Shattuck Labs Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Shattuck Labs hat ein Gesamteigenkapital von $110.6M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $128.6M bzw. $18.0M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$105.34m
Eigenkapital	US$110.62m
Gesamtverbindlichkeiten	US$18.00m
Gesamtvermögen	US$128.61m

Jüngste Berichte zur Finanzlage

Recent updates

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Oct 02

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Jun 15

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

Jun 28

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Mar 09

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Nov 23

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

Aug 11

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Jul 26

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 18

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Feb 25

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Nov 23

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Aug 24

Shattuck Labs names Abhinav Shukla as chief technical officer

Jun 01

Shattuck Labs EPS beats by $0.11, beats on revenue

May 10

Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

May 07

Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful?

Mar 08

We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely

Jan 12

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: STTKDie kurzfristigen Aktiva des Unternehmens ($114.4M) übersteigen seine kurzfristigen Passiva ($15.0M).

Langfristige Verbindlichkeiten: STTKDie kurzfristigen Vermögenswerte des Unternehmens ($114.4M) übersteigen seine langfristigen Verbindlichkeiten ($3.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: STTK ist schuldenfrei.

Schulden abbauen: STTK hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: STTK auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: STTK verfügt über eine ausreichende Liquiditätsreserve für 1.1 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 26.6% pro Jahr abnimmt.

Shattuck Labs Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Recent updates

New minor risk - Market cap size

Consensus revenue estimates decrease by 19%, EPS upgraded

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Price target decreased by 27% to US$8.00

Shattuck Labs, Inc. Announces Strategic Pipeline Prioritization to Include the Discontinuation of Its Clinical Program, SL-172154

Consensus revenue estimates increase by 23%

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Co-Founder recently bought US$50k worth of stock

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Price target decreased by 7.9% to US$14.50

Shattuck Labs, Inc. Announces Committee Appointments

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 159%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024

Consensus revenue estimates increase by 170%

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Financial Officer recently sold US$250k worth of stock

Chief Financial Officer notifies of intention to sell stock

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

New minor risk - Shareholder dilution

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

Price target increased by 21% to US$15.50

New major risk - Financial position

Consensus revenue estimates increase by 78%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml) and Higher-Mds) Patients At the American Society of Hematology (Ash) 2023 Annual Meeting

Consensus revenue estimates increase by 16%

Price target decreased by 21% to US$12.80

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 91%

New minor risk - Market cap size

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$2.03 loss

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Consensus forecasts updated

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 264%

High number of new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021)

Shattuck Labs, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.56 loss in 2Q 2021)

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$25.50

High number of new directors

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2022

Shattuck Labs Presents Preclinical Data At the 2022 American Association for Cancer Research (AACR) Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased to US$39.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Rosen Law Firm Files Securities Class Action Lawsuit Against Shattuck Labs, Inc

Lead Independent Director recently bought US$56k worth of stock

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Chief Financial Officer exercised options to buy US$250k worth of stock.

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$1.54 loss in 3Q 2020)